These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22367577)

  • 1. Should raising high-density lipoprotein cholesterol be a matter of debate?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    J Cardiovasc Med (Hagerstown); 2012 Apr; 13(4):254-9. PubMed ID: 22367577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?
    Shah PK
    Rev Cardiovasc Med; 2011; 12(2):e55-9. PubMed ID: 21796083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
    Stock J
    Atherosclerosis; 2013 Jun; 228(2):329-31. PubMed ID: 23623013
    [No Abstract]   [Full Text] [Related]  

  • 7. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
    Karalis I; Rensen PC; Jukema JW
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
    [No Abstract]   [Full Text] [Related]  

  • 9. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population: National Health and Nutrition Examination Survey 2005-2008.
    Christian JB; Bourgeois NE; Lowe KA
    J Cardiovasc Med (Hagerstown); 2011 Oct; 12(10):714-22. PubMed ID: 21881447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should HDL cholesterol levels be the primary target of cardiovascular disease risk assessment and therapy?
    Elis A
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):675-7. PubMed ID: 22894621
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipid abnormalities and cardiovascular risk in the elderly.
    Milionis HJ; Elisaf MS; Mikhailidis DP
    Curr Med Res Opin; 2008 Mar; 24(3):653-7. PubMed ID: 18218195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
    Reiner Z
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
    [No Abstract]   [Full Text] [Related]  

  • 14. Significant increase in high-density lipoprotein cholesterol with fibrates is associated with low pretreatment high-density lipoprotein cholesterol: findings from an outpatient clinic setting.
    Ramachandran S; Abbas A; Saraf S; Raju J; Jewkes C; Jones AF
    Metab Syndr Relat Disord; 2012 Jun; 10(3):189-94. PubMed ID: 22283634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-density lipoprotein cholesterol: current perspective for clinicians.
    Whayne TF
    Angiology; 2009; 60(5):644-9. PubMed ID: 19240106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
    Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
    Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor.
    Espinosa-Larrañaga F; Vejar-Jalaf M; Medina-Santillán R;
    Diab Vasc Dis Res; 2005 Oct; 2 Suppl 1():S1-8. PubMed ID: 16342610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
    Nicholls SJ; Lundman P; Tardif JC
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S20-4. PubMed ID: 20489416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel HDL-based therapeutic agents.
    Joy TR
    Pharmacol Ther; 2012 Jul; 135(1):18-30. PubMed ID: 22465158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.